A novel 15-hydroxyeicosatrienoic acid-substituted diacylglycerol (15-HETrE-DAG) selectively inhibits epidermal protein kinase C-beta.
Diacylglycerol containing 15-hydroxyeicosatrienoic acid (15-HETrE-DAG) was biosynthesized and examined for modulation of epidermal protein kinase C (PKC) activity. 15-HETrE-DAG competitively inhibited diolein-activated total PKC activity in a dose-dependent manner and further, selectively inhibited epidermal PKC-beta activity.
Cho
Y
Y
Institute of Human Nutrition, Columbia University, New York, NY 10032, USA.
Ziboh
V A
VA
D000818:Animals; D004075:Diglycerides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004817:Epidermis / Q000201:enzymology*; D006168:Guinea Pigs; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*
D004075:Diglycerides; D004791:Enzyme Inhibitors; D006893:Hydroxyeicosatetraenoic Acids; D007527:Isoenzymes; C095123:15-hydroxyeicosatrienoic acid; D011493:Protein Kinase C